Heredia Alonso, Davis Charles, Amoroso Anthony, Dominique Joyelle K, Le Nhut, Klingebiel Erin, Reardon Elise, Zella Davide, Redfield Robert R
Institute of Human Virology, Biotechnology Institute, University of Maryland, 725 West Lombard Street, Baltimore, MD 21201, USA.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4179-84. doi: 10.1073/pnas.0630584100. Epub 2003 Mar 18.
The beta-chemokines RANTES (regulated on activation, normal T cell expressed and secreted), macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta are the natural ligands of the HIV-1 coreceptor CCR5 and compete with the virus for receptor binding. We show that secretion of the beta-chemokines by activated lymphocytes starts before cellular DNA synthesis is detected and demonstrate that transient prolongation of the G(1) phase of the cell cycle by treatment with cytostatic drugs results in increased levels of the three chemokines in culture supernatants. Supernatants collected from peripheral blood mononuclear cells exposed to hydroxyurea, which arrests the cell cycle in late G(1), contained high levels of beta-chemokines. These supernatants were able to inhibit HIV-1 replication when added to cultures of infected lymphocytes. The observed antiviral effect likely was due to the increased levels of beta-chemokines RANTES, MIP-1alpha, and MIP-1beta because (i) supernatants greatly inhibited the replication of HIV-1 BaL, whereas they affected HIV-1 IIIb replication only slightly; (ii) neutralizing antibodies against the chemokines abrogated the antiviral effect of the supernatants; and (iii) the hydroxyurea concentrations shown to up-regulate chemokine levels were not sufficient to inhibit virus replication by depletion of intracellular nucleotide pools. Although antiviral properties have been reported previously for the cytostatic agents shown here to up-regulate beta-chemokine levels, our results provide an additional mechanism by which these drugs may exert antiviral activity. In summary, increased extracellular levels of anti-HIV-1 beta-chemokines resulting from transient prolongation of the G(1) phase of the lymphocyte cell cycle by treatment with cytostatic drugs may help to control the replication of CCR5-using strains of HIV-1.
β趋化因子RANTES(活化时调节、正常T细胞表达和分泌)、巨噬细胞炎性蛋白-1α(MIP-1α)和MIP-1β是HIV-1共受体CCR5的天然配体,可与病毒竞争受体结合。我们发现活化淋巴细胞分泌β趋化因子始于检测到细胞DNA合成之前,并证明用细胞抑制药物处理使细胞周期的G1期短暂延长会导致培养上清液中这三种趋化因子水平升高。从暴露于羟基脲的外周血单核细胞收集的上清液,羟基脲可使细胞周期停滞在G1晚期,其中含有高水平的β趋化因子。将这些上清液添加到感染淋巴细胞的培养物中时能够抑制HIV-1复制。观察到的抗病毒作用可能归因于β趋化因子RANTES、MIP-1α和MIP-1β水平升高,因为(i)上清液极大地抑制了HIV-1 BaL的复制,而对HIV-1 IIIb复制的影响很小;(ii)针对趋化因子的中和抗体消除了上清液的抗病毒作用;(iii)显示可上调趋化因子水平的羟基脲浓度不足以通过消耗细胞内核苷酸池来抑制病毒复制。尽管此前已报道此处显示的细胞抑制药物具有上调β趋化因子水平的抗病毒特性,但我们的结果提供了这些药物可能发挥抗病毒活性的另一种机制。总之,用细胞抑制药物处理使淋巴细胞细胞周期的G1期短暂延长导致细胞外抗HIV-1β趋化因子水平升高,这可能有助于控制使用CCR5的HIV-1毒株的复制。